drugset / Press release
Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan
2012-12-25 · Novo Nordisk A/S · original novonordisk.com ↗
Degludec
Insulin
Insulin degludec/insulin aspart
Insulin degludec/insulin aspart
insulin aspart
insulin degludec
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
regular insulin
Bagsværd, den 25. december 2012 - Novo Nordisk meddelte i dag, at det japanske ministerium for sundhed, arbejde og velfærd har godkendt Ryzodeg® (insulin degludec/insulin aspart) til behandling af diabetes. Yderligere information Medier: Mike Rulis +45 3079 3573 [email protected] Investorer: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Selskabsmeddelelse nr. 84 / 2012
The release as fetched from its publisher. novonordisk.com ↗